Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Free Cash Flow (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Free Cash Flow for 15 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 66.51% year-over-year to -$2.9 million, compared with a TTM value of -$10.8 million through Sep 2025, down 41.03%, and an annual FY2024 reading of -$8.3 million, down 25.83% over the prior year.
  • Free Cash Flow was -$2.9 million for Q3 2025 at BioRestorative Therapies, down from -$2.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$629364.0 in Q3 2021 and bottomed at -$2.9 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$1.7 million, with a median of -$1.7 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 126.74% in 2022, then grew 16.52% in 2023.
  • Year by year, Free Cash Flow stood at -$1.1 million in 2021, then tumbled by 44.83% to -$1.7 million in 2022, then increased by 0.02% to -$1.7 million in 2023, then tumbled by 40.53% to -$2.3 million in 2024, then fell by 25.64% to -$2.9 million in 2025.
  • Business Quant data shows Free Cash Flow for BRTX at -$2.9 million in Q3 2025, -$2.7 million in Q2 2025, and -$2.8 million in Q1 2025.